Literature DB >> 24047237

Extracellular matrix protein fibronectin induces matrix metalloproteinases in human prostate adenocarcinoma cells PC-3.

Sekhar Pal1, Kirat Kumar Ganguly, Amitava Chatterjee.   

Abstract

Studies on interaction of tumor cells with ECM components showed increased extracellular protease activity mediated by the family of matrix metalloproteinases (MMPs). Here we studied the effect of human prostate adenocarcinoma PC-3 cells-fibronectin (FN) interaction on MMPs and the underlying signaling pathways. Culturing of PC-3 cells on FN-coated surface upregulated MMP-9 and MMP-1. This response is abrogated by the blockade of α5 integrin. siRNA and inhibitor studies indicate possible involvement of phosphatidyl-inositol-3-kinase (PI-3K), focal adhesion kinase (FAK) and nuclear factor-kappaB (NF-κB) in FN-induced upregulation of MMPs. FN treatment also enhanced phosphorylation of FAK, PI3K, protein kinase B (PKB or Akt), nuclear translocation of NF-κB, surface expression of CD-44, and cell migration. Our findings indicate that, binding of PC-3 cells to FN, possibly via α5β1 integrin, induces signaling involving FAK, PI-3K, Akt, NF-κB followed by upregulation of MMP-9 and MMP-1. CD-44 may have role in modulating MMP-9 activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24047237     DOI: 10.3109/15419061.2013.833193

Source DB:  PubMed          Journal:  Cell Commun Adhes        ISSN: 1543-5180


  11 in total

1.  Extracellular matrix protein laminin induces matrix metalloproteinase-9 in human breast cancer cell line mcf-7.

Authors:  Sekhar Pal; Shuvojit Moulik; Anindita Dutta; Amitava Chatterjee
Journal:  Cancer Microenviron       Date:  2014-05-26

Review 2.  ILP-2: A New Bane and Therapeutic Target for Human Cancers.

Authors:  Zhiliang Zhang; Siqi Xiang; Ruxia Cui; Hang Peng; Roy Mridul; Mingjun Xiang
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

3.  Runx2-Smad signaling impacts the progression of tumor-induced bone disease.

Authors:  Xuhui Zhang; Jacqueline Akech; Gillian Browne; Stacey Russell; John J Wixted; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Int J Cancer       Date:  2014-08-05       Impact factor: 7.396

4.  Silibinin inhibits fibronectin induced motility, invasiveness and survival in human prostate carcinoma PC3 cells via targeting integrin signaling.

Authors:  Gagan Deep; Rahul Kumar; Anil K Jain; Chapla Agarwal; Rajesh Agarwal
Journal:  Mutat Res       Date:  2014-10       Impact factor: 2.433

5.  Cyr61: a potential therapeutic target for prostate cancer.

Authors:  Chang-Ming Lin; Chao-Zhao Liang
Journal:  Asian J Androl       Date:  2014 Sep-Oct       Impact factor: 3.285

6.  Fibronectin 1 promotes migration and invasion of papillary thyroid cancer and predicts papillary thyroid cancer lymph node metastasis.

Authors:  Shujun Xia; Chuandong Wang; Emily Louise Postma; Yanhua Yang; Xiaofeng Ni; Weiwei Zhan
Journal:  Onco Targets Ther       Date:  2017-03-22       Impact factor: 4.147

7.  Synergism from the combination of ulinastatin and curcumin offers greater inhibition against colorectal cancer liver metastases via modulating matrix metalloproteinase-9 and E-cadherin expression.

Authors:  Fei Shen; Wen-Song Cai; Jiang-Lin Li; Zhe Feng; Qi-Cai Liu; Huan-Qing Xiao; Jie Cao; Bo Xu
Journal:  Onco Targets Ther       Date:  2014-02-18       Impact factor: 4.147

8.  Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells.

Authors:  Moses O Oyewumi; Dharani Manickavasagam; Kimberly Novak; Daniel Wehrung; Nikola Paulic; Fouad M Moussa; Gregory R Sondag; Fayez F Safadi
Journal:  Oncotarget       Date:  2016-03-22

9.  METTL13 is downregulated in bladder carcinoma and suppresses cell proliferation, migration and invasion.

Authors:  Zhe Zhang; Guojun Zhang; Chuize Kong; Bo Zhan; Xiao Dong; Xiaojun Man
Journal:  Sci Rep       Date:  2016-01-14       Impact factor: 4.379

10.  Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7.

Authors:  Jochen Rutz; Sarah Thaler; Sebastian Maxeiner; Felix K-H Chun; Roman A Blaheta
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.